The WHO AFRO external quality assessment programme (EQAP): Linking laboratory networks through EQA programmes by Boeras, DI et al.
Boeras, DI; Peeling, RW; Onyebujoh, P; Yahaya, AA; Gumede-Moeletsi,
HN; Ndihokubwayo, JB (2016) The WHO AFRO external quality as-
sessment programme (EQAP): Linking laboratory networks through
EQA programmes. African journal of laboratory medicine, 5 (2).
a560. ISSN 2225-2002 DOI: 10.4102/ajlm.v5i2.560
Downloaded from: http://researchonline.lshtm.ac.uk/3430002/
DOI: 10.4102/ajlm.v5i2.560
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
http://www.ajlmonline.org Open Access
African Journal of Laboratory Medicine 
ISSN: (Online) 2225-2010, (Print) 2225-2002
Page 1 of 6 Lessons from the Field
Read online:
Scan this QR 
code with your 
smart phone or 
mobile device 
to read online.
Authors:
Debrah I. Boeras1 
Rosanna W. Peeling1 
Philip Onyebujoh2 
Ali A. Yahaya2
Hieronyma N. Gumede-
Moeletsi2
Jean B. Ndihokubwayo2
Affiliations:
1London School of Hygiene 
and Tropical Medicine, 
London, United Kingdom
2World Health Organization 
Regional Office for Africa, 
Brazzaville, Republic of Congo
Corresponding author:
Jean Ndihokubwayo, 
ndihokubwayoj@who.int
Dates:
Received: 31 Aug. 2016
Accepted: 31 Aug. 2016
Published: 17 Oct. 2016
How to cite this article:
Boeras DI, Peeling RW, 
Onyebujoh P, Yahaya AA, 
Gumede-Moeletsi HN, 
Ndihokubwayo JB. The WHO 
AFRO external quality 
assessment programme 
(EQAP): Linking laboratory 
networks through EQA 
programmes. Afr J Lab Med. 
2016;5(2), a560. http://dx.
doi.org/10.4102/ajlm.
v5i2.560
Copyright:
© 2016. The Authors. 
Licensee: AOSIS. This work 
is licensed under the 
Creative Commons 
Attribution License.
An external quality assurance programme (EQAP) is critical for laboratories to provide high-
quality test results. The EQAP encompasses: (1) investments in building human capacity; (2) 
investments in building laboratory management systems, infrastructure and management of 
quality systems; (3) well-written policies and procedures; (4) a quality control system, quality 
improvement (QI) and external quality assessment (EQA); and (5) accreditation standards1.
Laboratory professionals should routinely perform quality control testing to guarantee that test 
methods and equipment perform according to established standards. Laboratory professionals 
must participate in EQA/proficiency testing programmes in order to demonstrate that acceptable 
systems are in place and that specimens are collected and processed appropriately.
The objectives of the World Health Organization Regional Office for Africa (WHO AFRO) EQAP 
are:
•	 To support countries in their efforts to improve their laboratory quality management systems, 
including accreditation.
•	 To collect, analyse, and report laboratory EQA feedback data and use this information for 
corrective action and laboratory capacity strengthening.
•	 To establish recognised, accurate, and sustainable diagnostic practices using appropriate 
algorithms.
External Quality Assessment (EQA) surveys performed by the World Health Organization 
Regional Office for Africa (WHO AFRO) revealed the need for the strengthening of public 
health microbiology laboratories, particularly for testing of epidemic-prone diseases in the 
African Region. These surveys revealed common issues such as supply chain management, 
skilled personnel, logistical support and overall lack of quality standards. For sustainable 
improvements to health systems as well as global health security, deficiencies identified need 
to be actively corrected through robust quality assurance programmes and implementation of 
laboratory quality management systems.
Given all the pathogens of public health importance, an external quality assessment programme 
with a focus on vaccine-preventable diseases and emerging and re-emerging dangerous 
pathogens is important, and should not be stand-alone, but integrated within laboratory 
networks as seen in polio, measles, yellow fever and rubella.
In 2015, WHO AFRO collaborated with the US Centers for Disease Control and Prevention, 
the London School of Hygiene & Tropical Medicine and partners in a series of consultations 
with countries and national and regional EQA providers for the development of quality 
assurance models to support HIV point-of-care testing and monitoring. These consultations 
revealed similar challenges as seen in the WHO AFRO surveys. WHO AFRO brought forth 
its experience in implementing quality standards for health programmes, and also opened 
discussions on how lessons learned through such established programmes can be utilised to 
supporting and strengthening the introduction of early infant diagnosis of HIV and viral 
load point-of-care testing.
An optimised external quality assessment programme will impact the ability of countries to 
meet core capacities, providing improved quality management systems, improving the 
confidence of diagnostic network services in Africa, and including capacities to detect events 
of international public health importance.
The WHO AFRO external quality assessment 
programme (EQAP): Linking laboratory networks 
through EQA programmes
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World Health Organization Regional 
Office for Africa laboratory networks
WHO AFRO has established and monitored several 
national/regional laboratory networks linked by EQA 
programmes, including polio, measles and rubella, yellow 
fever, rotavirus and influenza laboratories, the Emerging 
and Dangerous Pathogens Laboratory Network, and the 
epidemic-prone bacterial diseases laboratory network, 
including tuberculosis. The Polio Laboratory Surveillance 
Network was established in Africa in 1993 to support 
the Global Polio Eradication Initiative. This laboratory 
network is made up of 16 laboratories in 15 countries, with 
each laboratory supporting at least one other country. Of 
these, 12 polio laboratories have integrated functions 
supporting measles, yellow fever and rotavirus programmes 
(Figure 1).
The Emerging and Dangerous Pathogens Laboratory 
Network has been established for the confirmation of viral 
haemorrhagic fevers in the WHO African region. The 
network consists of laboratories in 17 countries, categorised 
based on their capacity, as described in Figure 2.
The laboratory capacity to diagnose influenza infections by 
real-time PCR in the African Region has grown since the 2009 
pandemic. Presently, the regional influenza laboratory network 
comprises 30 national influenza reference laboratories in 30 
countries. Currently, 14 countries are registered as National 
Influenza Centres and are members of the WHO Global 
Influenza Surveillance Network in the African Region (Figure 
3). Since 2010, data on virological surveillance of the influenza 
virus have been received weekly from 22 countries. Presently, 
17 countries have a functional national influenza-like illness 
and severe acute respiratory infections surveillance system. In 
2015, more than 35 000 samples were tested, around 15% of 
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YF, yellow fever; AMR, antimicrobial resistance; ITD, intra-typic differentiation.
FIGURE 1: Vaccine-preventable disease networks in Africa. 
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WHO, World Health Organization; CC, Collaborating centres; VHF, viral haemorrhagic fever; EDP, Emerging and Dangerous Pathogens.
FIGURE 2: Emerging and Dangerous Pathogens Laboratory Network. 
which were positive. As of this writing, more than 21 000 
samples have been tested, and more than 10% were positive. 
This kind of information aids in identifying seasonal patterns 
of influenza in the region and informing influenza vaccination 
to prioritise high-risk groups.
External quality assessment 
programmes for the World Health 
Organization Regional Office for Africa
WHO AFRO collaborated with the National Institute for 
Communicable Diseases (NICD) in South Africa as the EQA 
provider.2 The WHO/NICD microbiology EQAP was started 
in May 2002 and currently, over 90 laboratories in 45 African 
countries participate in this programme at a cost of USD 
150 000/year (Figure 4).
Its objective is to assess laboratory capacity to detect 
epidemic-prone diseases (enteric and meningitis pathogens 
and plague). In addition, this programme assesses laboratory 
capacity to diagnose malaria and tuberculosis.3 The NICD 
has the capacity to produce, perform quality control of and 
distribute samples for the EQAP. The resulting data goes to 
both NICD and WHO AFRO, belonging to the WHO AFRO 
EQAP programme.
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The EQAP conducts three surveys (shipments) per calendar 
year, with 2 to 4 disease components per survey:
•	 Bacteriology discipline: six simulated specimens containing 
organisms isolated from enteric, meningeal and routine 
clinical samples for microscopy, culture, identification 
and/or antimicrobial susceptibility testing.
•	 Plague discipline: two simulated samples for diagnostic 
tests for Yersinia pestis, including microscopy.
•	 Tuberculosis microscopy: 10 slides per panel for reporting 
on the presence of acid-fast bacilli using the International 
Union for Tuberculosis and Lung Disease smear-grading 
system.
•	 Malaria microscopy: 20 slides per panel to assess ability 
to diagnose malaria species and to count parasites.
Laboratories for enteric and meningitis pathogens were 
graded based on a score depending on their capacity to do 
the following:
1. Microscopy: clinically important, basic skill, relevant.
2. Culture and identification.
3. Serotyping/serogrouping: important to evaluate disease 
prevention and control strategies.
4. Antimicrobial agents selected for testing.
5. Antimicrobial susceptibility testing.
In the region, it was observed that errors in antimicrobial 
resistance testing included inappropriate selection of 
antibiotics, guideline availability, no adherence to 
guidelines, no control/reference strains, and incorrect 
results and interpretation.4 These surveys reflect common 
issues, such as shortages of supplies and human resources, 
as well as the critical need for national standards and 
quality assessments.5
Diagnostic challenges for 
tuberculosis control
As shown in Figure 5, there are a total of 15 847 laboratories 
in the region that have the capacity to perform tuberculosis 
smear microscopy, with less than half (6798) subscribing to 
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FIGURE 3: The World Health Organization African Region influenza laboratory network. 
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an EQA programme. Of the 7923 laboratories that can 
perform tuberculosis culture and drug-susceptibility testing, 
only 91 subscribed to an EQA programme for culture and 53 
for drug-susceptibility testing services. It also highlights the 
enormous challenges inherent in meeting the WHO ‘End TB’ 
Strategy which advocates for universal drug-susceptibility 
testing coverage. Now, instead of performing cultures, many 
facilities are moving to molecular testing, the quality of 
which can be assured through a fee-based National Health 
Laboratory Services tuberculosis programme for the Cepheid 
GeneXpert®.6
External quality assessment 
programme corrective action
As part of EQA, laboratories with low performance in the 
EQAP receive feedback, training and technical support 
aimed at instituting corrective action. In a joint collaboration, 
the EQAP and NICD provide feedback and corrective action 
to all participating laboratories in the three official working 
languages in the WHO African Region (English, French and 
Portuguese). On-site and regional training sessions are also 
provided. As part of technical support, standard operating 
Enteric and meningis pathogens
Enteric, meningis and plague pathogens,
TB and malaria microscopy
 EQA regional support (NICD)
FIGURE 4: World Health Organization-National Institute for Communicable Diseases microbiology external quality assessment programme for potential bacterial 
epidemics, tuberculosis and malaria in the African region (since 2002). 
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procedures and guidelines are made available. Specifically, 
guidelines and standard operating procedures for laboratories 
performing antimicrobial susceptibility testing are made 
available in addition to laboratory bench training workshops.
Way forward
In 2015, WHO AFRO collaborated with the US Centers for 
Disease Control and Prevention, the London School of 
Hygiene & Tropical Medicine and partners in a series of 
consultations with countries and international, national and 
regional EQA providers for the development of quality 
assurance models to support HIV point-of-care testing. 
Participants consulted revealed similar challenges with 
supply chain management, skilled personnel, logistical 
support and overall lack of quality standards. WHO AFRO 
provided experiential oversight in implementing quality 
standards for health programmes, as well as facilitating 
discussions on how lessons learned through such established 
programmes should be utilised in supporting and 
strengthening the introduction of HIV early infant diagnosis 
and viral load point-of-care testing.
Conclusion
The EQAP has provided a clearer understanding of the 
capacities of participating laboratories to produce accurate 
results. This international EQAP provides a unique 
opportunity for African national public health laboratories 
to continuously assess and improve their laboratory 
performance, identifying their strengths, limitations and on-
going challenges. The EQAP facilitates an improvement in 
the confidence of test results from diagnostic networks that 
impacts on treatment capacities by the requesting treatment 
centres.
Given all the pathogens of public health importance, the 
EQAP should not be stand-alone, but rather integrated 
within laboratory networks, as seen with polio, measles, 
yellow fever and rubella. Grouping them together provides 
economy of scale for cost-effectiveness and efficiencies for 
ease of training and reporting. The EQAP needs to emphasise 
the utility of such programmes in improving services for 
both vaccine-preventable diseases and emerging and re-
emerging dangerous pathogens.
Finally, an optimised EQAP will impact the ability of 
countries to meet International Health Regulations (2005) 
core capacities, including the capacity to detect events of 
international public health importance. This programme has 
allowed WHO AFRO to identify the capacities and resources 
needed by countries for sustainable improvement and 
competency of diagnostic services throughout Africa. 
Improved quality of laboratory networks produces highly-
accurate surveillance data which is required to estimate 
disease burden in countries, identify outbreaks and inform 
strategies for disease control and prevention.
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